LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.15, MarketWatch Earnings reports. LAVA Therapeutics had a negative return on equity of 51.14% and a negative net margin of 167.49%.
LAVA Therapeutics Price Performance
LVTX traded up $0.02 on Friday, reaching $1.50. The company had a trading volume of 2,433 shares, compared to its average volume of 219,694. The company’s fifty day moving average is $1.44 and its 200 day moving average is $1.74. LAVA Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $7.38. The company has a quick ratio of 5.31, a current ratio of 5.31 and a debt-to-equity ratio of 0.02.
Institutional Investors Weigh In On LAVA Therapeutics
Several large investors have recently modified their holdings of the company. Bruce & Co. Inc. purchased a new position in LAVA Therapeutics in the 4th quarter worth approximately $350,000. PNC Financial Services Group Inc. boosted its holdings in shares of LAVA Therapeutics by 30.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 65,000 shares of the company’s stock valued at $132,000 after acquiring an additional 15,000 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of LAVA Therapeutics by 20,566.7% in the first quarter. Bank of America Corp DE now owns 32,240 shares of the company’s stock worth $54,000 after buying an additional 32,084 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in LAVA Therapeutics during the 4th quarter worth approximately $66,000.
Wall Street Analysts Forecast Growth
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
- Five stocks we like better than LAVA Therapeutics
- What is Short Interest? How to Use It
- Williams-Sonoma is a steal for buy-and-hold investors
- What is the Nikkei 225 index?
- A closer look at Warren Buffett’s latest surprise purchase
- Most active stocks: Dollar volume vs share volume
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.